Karyopharm Therapeutics
The biggest 3000 companies in the U.S. in the year of 2025.
Rating Overview
Rating Criteria
Rating Criteria Detail
Corporate Weaponization
Criteria:
Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Risk Level:
LowerRationale:
Karyopharm Therapeutics has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (1).
Criteria:
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Risk Level:
LowerCriteria:
Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.
Risk Level:
HighRationale:
Karyopharm Therapeutics offers diversity and inclusion training programs to its employees (1). The company prioritizes diversity over merit in its board composition. From its Proxy Statement: “The Board strengthened its consideration of diversity factors when evaluating potential director nominees, including a commitment in both the charter of the Nominating, Corporate Governance & Compliance Committee and the Company’s Corporate Governance Guidelines to include diversity among the factors it considers when evaluating potential candidates” (2). Karyopharm Therapeutics does not provide viewpoint protections for its employees (3).
Corporate Governance and Public Policy
Criteria:
Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.
Risk Level:
MediumCriteria:
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Risk Level:
LowerRationale:
Karyopharm Therapeutics has not used corporate funds to advance ideological causes, organizations, or policies (1).